New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For GILD From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent GILD news | >>
October 31, 2014
12:02 EDTGILDStocks with call strike movement; GILD SLV
Subscribe for More Information
09:49 EDTGILDAbbVie says will not discuss pricing strategy for HCV treatment
Subscribe for More Information
09:36 EDTGILDActive equity options trading
Subscribe for More Information
09:32 EDTGILDAbbVie now sees HCV market as even better than it did a year ago
Subscribe for More Information
October 30, 2014
16:00 EDTGILDOptions Update; October 30, 2014
Subscribe for More Information
October 29, 2014
17:57 EDTGILDGilead drop looks like good entry point, Barron's says
Subscribe for More Information
16:02 EDTGILDOptions Update; October 29, 2014
Subscribe for More Information
12:08 EDTGILDStocks with call strike movement; GILD DAL
Subscribe for More Information
10:47 EDTGILDGilead price target raised to $133 from $109 at Leerink
Subscribe for More Information
10:17 EDTGILDGilead retreats after Hepatitis C drug sales miss expectations
Shares of drug maker Gilead (GILD) are falling after the company last night announced lower than expected third quarter profits and reported sales of its Hepatitis C treatment, Sovaldi, that came in below expectations. WHAT'S NEW: Gilead reported Q3 earnings per share of $1.84, versus analysts' consensus estimate of $1.92. The company's revenue came in slightly above expectations. Gilead said its Sovaldi drug had generated $2.8B of sales last quarter. On average, analysts had expected sales of the drug to come in at $2.93B. Sales of Sovaldi dropped 20% in Q3 versus Q2. However, the company said on its earnings conference call that the launch of its new Hepatitis C treatment, Harvoni, was off to a strong start. ANALYST REACTION: In a note to investors earlier today, Bernstein analyst Geoffrey Porges wrote that Gilead's Q3 revenue and EPS were reduced by one-time events. Its EPS would have easily beaten expectations if the company did not have to pay one-time taxes related to the Affordable Care Act, Porges stated. The lower than expected Sovaldi sales were caused by a variety of factors, including anticipation of the Harvoni launch, the analyst believes. The challenges facing Sovaldi should not affect Harvoni's performance in Q4 and 2015, added Porges, who remains very upbeat on the company's overall Hepatitis C franchise for the near to medium term. He kept a $130 price target and Outperform rating on the shares. Analysts at UBS also remained positive on Gilead, writing that the company had a good quarter with its HIV franchise that resulted in a top-line beat despite the lower than expected Sovaldi sales. The firm said it remains bullish on the Harvoni launch and sees potential upside to estimates. UBS reiterated its Buy rating and $125 price target on Gilead shares. OTHERS TO WATCH: Other pharmaceutical companies offering and developing Hepatitis C treatments include Johnson & Johnson (JNJ) and Abbvie (ABBV). PRICE ACTION: In early trading, Gilead fell 2% to $111.25.
09:42 EDTGILDActive equity options trading
Subscribe for More Information
09:19 EDTGILDOn The Fly: Pre-market Movers
UP AFTER EARNINGS: Goodyear Tire (GT), up 10%... Electronic Arts (EA), up 3.7%... ZELTIQ (ZLTQ), up 9%... Eaton (ETN), up 2.3%... Anadarko (APC), up 2%... U.S. Steel (X), up 7.7%... IAC (IACI), up 3.6%. ALSO HIGHER: Fiat Chrysler (FCAU), up 12% after reporting quarterly results, announcing plan to spin off Ferrari... Cara Therapeutics (CARA), up 17.8% after HAL trial of IV formulation of CR845 met primary endpoint... Jamba (JMBA), up 4% after upgraded at Wedbush. DOWN AFTER EARNINGS: Facebook (FB), down 5.7%... Gilead (GILD), down 3.2%... Ralph Lauren (RL), down 2.3%... SodaStream (SODA), down 3%... Garmin (GRMN), down 5%... Applied Micro Circuits (AMCC), down 9.9%... STMicroelectronics (STM), down 10%... Ballard Power (BLDP), down 8.7%... Hershey (HSY), down 3.3%... Deutsche Bank (DB), down 2.3%... McKesson (MCK), down 2%. ALSO LOWER: Sanofi (SNY), down 5.7% after downgraded at various firms including Barclays and BofA/Merrill after the company's board removed Christopher Viehbacher as CEO... InvenSense (INVN), down 22%, downgraded at Pacific Crest, Northland and Piper Jaffray following the company's Q2 earnings results... CareTrust REIT (CTRE), down 3.6% after acquiring Cross Healthcare Seniors housing portfolio... Orbital (ORB), down 16% after Orb-3 launch mishap... American Realty (ARCP), down 22% after announcing resignations of CFO, CAO.
08:48 EDTGILDGilead Q3 results good despite Sovaldi miss, says UBS
Subscribe for More Information
07:07 EDTGILDGilead Harvoni comments very encouraging, says Bernstein
Subscribe for More Information
October 28, 2014
18:42 EDTGILDOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTGILDGilead says to date 117K patients treated with Sovaldi
Subscribe for More Information
16:10 EDTGILDGilead narrows FY14 net product sales guidance to $22B-$23B from $21B-$23B
Narrows FY14 non-GAAP product gross margin guidance to 86%-88% from 85%-88%.
16:07 EDTGILDGilead reports Q3 product sales $5.97B vs. $2.71B last year
Subscribe for More Information
16:06 EDTGILDGilead reports Q3 EPS $1.84, consensus $1.92
Subscribe for More Information
14:15 EDTGILDGilead October weekly 113 straddle priced for 5% move into Q3
Subscribe for More Information
13:20 EDTGILDGilead volatility increases into Q3 and outlook
Gilead October weekly call option implied volatility is at 69, November is at 43, December is at 40, and January is at 37; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
09:37 EDTGILDActive equity options trading
Subscribe for More Information
October 27, 2014
16:00 EDTGILDOptions Update; October 27, 2014
iPath S&P 500 VIX Short-Term Futures down 52c to 32.66. Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR TWTR AMZN M NQ GILD C FB NFLX
08:27 EDTGILDGilead volatility elevated into Q3 and outlook
Gilead October weekly call option implied volatility is at 63, November is at 38, December and January is at 33; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
07:22 EDTGILDAmerican College of Chest Physicians to hold a conference
Subscribe for More Information
October 24, 2014
16:02 EDTGILDOptions Update; October 24, 2014
Subscribe for More Information
11:55 EDTGILDStocks with call strike movement; YHOO GILD
Subscribe for More Information
October 23, 2014
08:35 EDTGILDGilead weekly volatility increases into Q3 and outlook
Gilead October weekly 31 call option implied volatility is at 43, December and January is at 33; compared to its 26-week average of 33 according to Track Data, suggesting larger near term price movement into the expected release of Q3 results on October 28.
October 22, 2014
09:38 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR YHOO BAC GILD FB THRX DOW CAR
07:35 EDTGILDCardiometabolic Health Congress to hold annual meeting
Subscribe for More Information
October 21, 2014
09:37 EDTGILDActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL PBR AMZN C TWTR CVX VZ MCD GILD TXN
08:45 EDTGILDGilead Hep C drug barely used in California prisons due to cost, SFGate reports
Subscribe for More Information
October 20, 2014
09:36 EDTGILDActive equity options trading on open
Subscribe for More Information
October 17, 2014
16:01 EDTGILDOptions Update; October 17, 2014
iPath S&P 500 VIX Short-Term Futures down 1.75 to 38.58 Option volume leaders: AAPL TSLA TWTR AMZN FB NFLX GILD CLF PBR according to Track Data.
09:38 EDTGILDActive equity options trading on
Subscribe for More Information
<< 1 | 2 | all recent GILD news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use